UVA Researchers Map 500,000 Chimeric RNAs in Cancer
A University of Virginia team mapped chimeric RNAs across more than 1,000 cancer cell lines and found some can be switched off to stop cancer cell growth.
Updated on Nov. 12, 2026 in Cancer
Live Poll
Do you trust scientists to deliver meaningful new cancer treatments in the coming years?
Researchers at the University of Virginia School of Medicine mapped more than 500,000 chimeric RNAs across more than 1,000 cancer cell lines. Switching off certain chimeric RNAs stopped cancer cell growth or killed the cells.
Why it matters
Chimeric RNAs are molecules built from parts of different genes, and identifying which ones drive cancer cell growth could point to new treatment targets and detection methods. The strongest results were seen in breast cancer, with additional data covering colon, brain and prostate cancers.
The study mapped more than 500,000 chimeric RNAs across more than 1,000 cancer cell lines, a scale that does not yet have a reported baseline for comparison. It remains unclear which specific chimeric RNAs will prove clinically useful and how the cell-line results will translate to human patients.
The players
University of Virginia School of Medicine
The medical school of the University of Virginia, a public research university in Charlottesville, Virginia, where the chimeric RNA research was conducted.
Dr. Hui Li
A professor of pathology at the UVA School of Medicine who is a leading figure in the study of chimeric RNAs in cancer.
The details
The team switched off certain chimeric RNAs and observed that cancer cell growth stopped or the cells died. Dr. Hui Li, a professor of pathology at the UVA School of Medicine, led the work with a UVA graduate student, and she hopes other researchers will use the data to find new targets and ways to detect cancer.
Timeline
November 12, 2026: Article published on the UVA chimeric RNA cancer research
Big Picture
The study extends large-scale cancer profiling efforts such as The Cancer Genome Atlas, which catalogued somatic DNA alterations across tumor types, into the realm of chimeric RNA molecules. Mapping these fusion transcripts at the scale of more than 1,000 cell lines moves the field toward identifying RNA-level drivers alongside the genomic ones.
At this stage the findings are laboratory results in cell lines, so no new treatment or test is available to patients yet. Readers should understand that any eventual therapy would first need to pass clinical trials before reaching clinics.
The takeaway
Research like this shows that cancer biology is revealing new layers of molecular activity beyond the DNA mutations that have long dominated the field. Patients and families should watch for clinical trials that test these findings in people before expecting changes in care.
Further reading
Explore more Cancer research and developments from across the health desk.
Source note: This article includes information reported by 29news.
Live Poll
Do you trust scientists to deliver meaningful new cancer treatments in the coming years?
